Navigation Links
Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
Date:1/3/2012

PHILADELPHIA, Jan. 3, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Biotech Showcase 2012 Conference.

Dr. Mooney will make a presentation to prospective corporate partners and investors on Monday, January 9th at 2:00 PM PST.  The Company's presentation will be delivered at the Parc 55 Wyndham in San Francisco.  

About Biotech Showcase (Innovation – Opportunity – Collaboration)

Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences that annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action.  To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®.  Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.  Visit our website for more information: www.ebdgroup.com/bts.

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

For More Information:
Christine Olimpio                                                                
Director, Investor Relations & Corporate Communications                      
(215) 717-4104                                                                   

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
2. AuraSense Therapeutics Secures Series B Equity Investment
3. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
4. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
5. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
6. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
7. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
8. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
9. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
10. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
11. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
(Date:4/26/2016)... , April 26, 2016 ... Microbial identification Market Size, Share, Development, Growth ... Insights by Product (Consumables, Instruments and Software ... Genotypic Method), by Application (Diagnostic Application, Food ... Application) and by End User (Hospitals, Pharmaceutical ...
Breaking Medicine Technology:
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy ... prescription medications from over 180 American pharmaceutical companies for $35 per month, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... offering, the Protocol Calendar Exchange , is officially open to all sponsors ... calendars available for sites to download into their clinical trial management system (CTMS), ...
(Date:4/28/2016)... ... 2016 , ... On Thursday, April 14 orthopaedic surgeon ... Institute in Vail, Colorado, attended the American Academy of Orthopaedic Surgeons (AAOS) ... musculoskeletal disorders that are affecting millions of Americans today. Dr. LaPrade and many ...
(Date:4/28/2016)... Valley, California (PRWEB) , ... ... ... Inc. (AGNITY) a leading global provider of intelligent business communication applications and ... and go-live of its Number Portability solution at Bestel’s Communications Network. ...
Breaking Medicine News(10 mins):